The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions
- PMID: 20209622
- DOI: 10.1002/cncy.20071
The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions
Abstract
Background: The distinction of benign from malignant mesothelial proliferations in cytologic specimens can be problematic. In this study, the authors investigated the utility of immunohistochemical (IHC) markers in making this distinction.
Methods: Archival paraffin-embedded cell blocks of pleural and peritoneal fluids from 52 patients with malignant mesothelioma (MM) and 64 patients with reactive mesothelial hyperplasia (MH) were retrieved. IHC stains included desmin, epithelial membrane antigen (EMA), glucose-transport protein 1 (GLUT-1), Ki67, and p53.
Results: Desmin was positive in 84% (54 of 64) cases of reactive MH and in 6% (3 of 52) of MM cases (P < .001). EMA was positive in 9% (6 of 64) of benign and 100% (52 of 52) of malignant cases (P < .001). GLUT-1 was positive in 12% (5 of 43) of benign and 47% (7 of 15) of malignant cases. Ki67 showed strong nuclear positivity in >40% of mesothelial cells in 9% (6 of 64) of benign and 16% (8 of 49) of malignant cases (P = .38). p53 showed strong nuclear positivity in 2% (1 of 46) of benign and 47% (7 of 15) of malignant cases (P < .001). EMA positivity and desmin negativity were found in 2% (1 of 64) of reactive MH cases and 98% (49 of 52) of MM cases (P < .001). EMA negativity and desmin positivity were found in 86% (55 of 64) of reactive MH cases and 0% of MM cases.
Conclusions: The combination of positive EMA and negative desmin strongly favors MM; conversely, a combination of negative EMA and positive desmin favors a reactive process. Likewise, strong membranous positivity for GLUT-1 and/or strong nuclear staining for p53 favors a mesothelioma. Ki67 proliferative index showed no significant difference between reactive MH and MM cases.
(c) 2010 American Cancer Society.
Comment in
-
The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.Cancer Cytopathol. 2010 Aug 25;118(4):225; author reply 225. doi: 10.1002/cncy.20088. Cancer Cytopathol. 2010. PMID: 20731007 No abstract available.
Similar articles
-
Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.Arch Pathol Lab Med. 1996 Oct;120(10):959-66. Arch Pathol Lab Med. 1996. PMID: 12046609
-
The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.J Pathol. 1999 Oct;189(2):251-7. doi: 10.1002/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO;2-F. J Pathol. 1999. PMID: 10547583
-
[A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].Pneumonol Alergol Pol. 2007;75(1):57-69. Pneumonol Alergol Pol. 2007. PMID: 17541913 Polish.
-
The separation of benign and malignant mesothelial proliferations.Am J Surg Pathol. 2000 Sep;24(9):1183-200. doi: 10.1097/00000478-200009000-00001. Am J Surg Pathol. 2000. PMID: 10976692 Review.
-
The separation of benign and malignant mesothelial proliferations.Arch Pathol Lab Med. 2012 Oct;136(10):1217-26. doi: 10.5858/arpa.2012-0112-RA. Arch Pathol Lab Med. 2012. PMID: 23020727 Review.
Cited by
-
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.Mod Pathol. 2015 Aug;28(8):1043-57. doi: 10.1038/modpathol.2015.65. Epub 2015 May 29. Mod Pathol. 2015. PMID: 26022455
-
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.J Thorac Dis. 2018 Jan;10(Suppl 2):S342-S352. doi: 10.21037/jtd.2017.10.88. J Thorac Dis. 2018. PMID: 29507804 Free PMC article. Review.
-
Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models.PLoS One. 2017 Oct 23;12(10):e0186137. doi: 10.1371/journal.pone.0186137. eCollection 2017. PLoS One. 2017. PMID: 29059207 Free PMC article.
-
Detection of carcinoma in serous effusions: a review.Am J Cancer Res. 2021 Jan 1;11(1):43-60. eCollection 2021. Am J Cancer Res. 2021. PMID: 33520359 Free PMC article. Review.
-
β-catenin expression in benign and malignant pleural disorders.Int J Clin Exp Pathol. 2011;4(8):742-7. Epub 2011 Oct 30. Int J Clin Exp Pathol. 2011. PMID: 22135721 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous